#USA #Pittsburgh #Neuroma Pain #Renerva #PNM-CAP

Renerva's Breakthrough in Neuroma Pain Management

Renerva, Inc., a pioneering medical device company focused on innovations for peripheral nerve injuries, has made significant strides in the field of neuropathic pain management. Recently, the company announced the successful implantation of its PNM-CAP™ device in a clinical trial, making it the first of its kind used in humans.

This landmark procedure, carried out at The Ohio State University Wexner Medical Center, was supervised by Dr. Amy M. Moore, who leads the surgical team and is the Interim Dean of the College of Medicine at the university. The PNM-CAP device is designed specifically to prevent disorganized nerve growth, known as neuromas, which often lead to severe pain when nerve recovery is either not possible or not desired. Neuromas are particularly problematic for amputees and patients suffering from nerve injuries, as they can cause ongoing, debilitating pain and significantly diminish life quality. In many cases, this type of pain leads to increased opioid use, compounding the issue of dependence on these powerful medications.

Lorenzo Soletti, CEO of Renerva, expressed the significance of this achievement: "Transitioning to a clinical-stage company with the implantation of our first patient is a monumental milestone. Our team has executed effectively, moving from FDA Investigational Device Exemption approval to first-in-human implantation in just a few months. We are preparing for regulatory clearance and commercial launch, enabling us to deliver this vital technology to patients and set a new standard of care."

The current study aims to evaluate the efficacy of the PNM-CAP device on patients undergoing nerve management for intractable neuropathic pain. Key outcomes include assessing pain reduction, decrease in opioid consumption, and overall patient quality of life—all of which align with the metrics of value-based healthcare. Dr. Moore emphasized the importance of this trial by stating, "Treating the first patient with PNM-CAP is a critical step toward addressing severe chronic pain of nerve origin, which is difficult to manage. In the operating room, the device was easy to use, seamlessly fitting into our standard surgical procedure."

The implications of this device are profound, especially given that the United States sees nearly 500,000 new extremity amputations annually. The advent of the PNM-CAP device could dramatically enhance the quality of life for many patients, aiding in more comfortable prosthesis fittings and reducing the likelihood of even further pain complications. Renerva's device has the potential to minimize chronic pain in amputees, which would decrease reliance on pain management medications, ultimately alleviating the risks of developing opioid use disorders.

Looking ahead, Renerva anticipates achieving FDA market clearance for their PNM-CAP device in the near future, which will facilitate a swift commercial rollout and enable greater clinical accessibility. Such progress could reshape the treatment landscape for those struggling with nerve pain due to injury or amputation.

Renerva is dedicated to advancing solutions for peripheral nerve injuries and maintaining focus on patients affected by extremity amputations. With its headquarters located in Pittsburgh, Pennsylvania, Renerva is committed to transforming neuropathic pain management and improving life quality through innovative medical technology. More information about their developments can be found at Renerva's website.